来源：市场资讯（来源：真灼财经）在医疗行业改革不断深化、医疗器械行业竞争日趋激烈的背景下，作为中国领先的医疗器械企业的$普华和顺(HK1358)发布了2025 年上半年的业绩。数据显示，2025 年上半年普华和顺实现总营收 4.144 亿元，同比增长 22.4%；期内溢利 0.866 亿元，同比下降 7.5%。其中，三大核心业务呈现差异化发展态势：血液净化业务实现销售收入 2.974 亿元，同比...
Source Link来源：市场资讯（来源：真灼财经）在医疗行业改革不断深化、医疗器械行业竞争日趋激烈的背景下，作为中国领先的医疗器械企业的$普华和顺(HK1358)发布了2025 年上半年的业绩。数据显示，2025 年上半年普华和顺实现总营收 4.144 亿元，同比增长 22.4%；期内溢利 0.866 亿元，同比下降 7.5%。其中，三大核心业务呈现差异化发展态势：血液净化业务实现销售收入 2.974 亿元，同比...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.